New hope for tough prostate cancer: drug cocktail trial launches
NCT ID NCT06059118
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tests a sequence of three drugs—DFMO, high-dose testosterone, and enzalutamide—in 50 men with metastatic castration-resistant prostate cancer that has progressed on standard therapy. The goal is to see if this combination can lower PSA levels and delay cancer growth. Participants must be asymptomatic and have castrate testosterone levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
DFMO (eflornithine), testosterone cypionate, and enzalutamide
What this could lead to
If successful, this could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is an early Phase 2 trial with only 50 participants, so results may not apply to everyone. The combination therapy may cause significant side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center
RECRUITINGBaltimore, Maryland, 21287, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact